[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438662":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":39,"responsibleParty":53,"collaborators":10,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaccination Group",null,"Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and received COVID-19 vaccination (SinoVac or BioNTech).",[13],"Diagnostic Test: Laboratory tests and Montreal Cognitive Assessment",{"label":15,"type":10,"description":16,"interventionNames":17},"Control Group","Citizens who received baseline cognitive assessment and evaluation of metabolic risk factors from the CUHK Brain Health Longitudinal Study. Baseline micro- and macro-cerebrovascular abnormalities were evaluated by MRI brain on recruitment and have not received any COVID-19 vaccines nor clinically\u002Fserologically evident SARS-CoV-2 infection.",[13],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Laboratory tests and Montreal Cognitive Assessment","Laboratory tests at baseline and 16 weeks (+\u002F-4 weeks) after 2nd dose of vaccine and serological testing for IgG antibody. Participants who have a scheduled vaccination date shall undergo an MRI brain 16 weeks (+\u002F-4 weeks) after the second dose of COVID-19 vaccination (either SinoVac or BioNTech). A face-to-face assessment 16 weeks (+\u002F-4 weeks) will also be conducted after the 2nd dose of COVID-vaccine for evaluation of any clinical events, followed by a phone visit every 6 months. Cognitive assessment by MoCA will be performed at baseline, 16 weeks (+\u002F-4 weeks) then every 12 months after the 2nd dose of COVID-19 vaccine.",[9],{"type":20,"name":21,"description":25,"armGroupLabels":26,"otherNames":10},"Laboratory tests at baseline and serological testing for IgG antibody to exclude past COVID-19 infection. The timing of the second MRI brain, laboratory tests, clinical and cognitive assessment will be matched with the timing in the vaccination group are available.",[15],[28],{"name":29,"affiliation":5,"role":30},"Bonaventure Yiu Ming IP, MB ChB","PRINCIPAL_INVESTIGATOR",[32,36],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},"CONTACT","852-28902002","bonaventureip@cuhk.edu.hk",{"name":37,"role":33,"phone":34,"phoneExt":10,"email":38},"Thomas Wai Hong LEUNG, MB ChB","drtleung@cuhk.edu.hk",[40],{"facility":5,"status":41,"city":42,"state":10,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Hong Kong","HK",{"type":45,"coordinates":46},"Point",[47,48],114.17469,22.27832,{"lat":48,"lon":47},[51,52],{"name":29,"role":33,"phone":34,"phoneExt":10,"email":35},{"name":37,"role":33,"phone":34,"phoneExt":10,"email":38},{"type":30,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Dr. IP Yiu Ming Bonaventure","Clinical Lecturer","100438662",false,"NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",true,"ALL","18 Years",{"count":66,"type":67},500,"ESTIMATED","OBSERVATIONAL","Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[71,72,73,74,75,76,77,78,79,80],"Stroke","Stroke, Acute","Stroke, Ischemic","Dementia","Brain Ischemia","Alzheimer Disease","Brain Diseases","Major Adverse Cardiovascular Event","Arterial Thromboembolism","Venous Thromboembolism","2026-02-21",{"date":83,"type":84},"2026-02-24","ACTUAL",{"date":86,"type":84},"2021-07-05",{"date":88,"type":67},"2026-12-31",{"name":5,"class":6},1]